# LifeStance Health Group Announces Pricing of Secondary Public Offering
Canonical URL: https://biopharmsignal.com/news/LFST/lifestance-health-group-announces-pricing-of-secondary-public-offering
Ticker: LFST
Company: LifeStance Health
Source: LifeStance Health
Published: 2026-05-08 02:18 EST
Original Source URL: https://investor.lifestance.com
## Summary

SCOTTSDALE, Ariz., May 07, 2026 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (“LifeStance” or the “Company”) (Nasdaq: LFST), one of the nation’s largest providers of virtual and in-person outpatient mental health care, today announced the pricing of a secondary underwritten public offering of

## Article Body
SCOTTSDALE, Ariz., May 07, 2026 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (“LifeStance” or the “Company”) (Nasdaq: LFST), one of the nation’s largest providers of virtual and in-person outpatient mental health care, today announced the pricing of a secondary underwritten public offering of
## Recent Company News
- 2026-05-08 02:18 EST — [LifeStance Health Group Announces Pricing of Secondary Public Offering](https://biopharmsignal.com/news/LFST/lifestance-health-group-announces-pricing-of-secondary-public-offering) — Source: LifeStance Health
- 2026-05-07 10:00 EST — [LifeStance Reports First Quarter 2026 Results](https://biopharmsignal.com/news/LFST/lifestance-reports-first-quarter-2026-results) — Source: LifeStance Health
- 2026-04-29 20:10 EST — [LifeStance to Present at Upcoming Investor Conferences](https://biopharmsignal.com/news/LFST/lifestance-to-present-at-upcoming-investor-conferences) — Source: LifeStance Health
- 2026-04-16 20:10 EST — [LifeStance to Host First Quarter 2026 Earnings Conference Call on May 7, 2026](https://biopharmsignal.com/news/LFST/lifestance-to-host-first-quarter-2026-earnings-conference-call-on-may-7-2026) — Source: LifeStance Health
- 2026-04-09 13:00 EST — [LifeStance Publishes Outcomes Data Validating the Benefit of Mental Health Treatment at Scale](https://biopharmsignal.com/news/LFST/lifestance-publishes-outcomes-data-validating-the-benefit-of-mental-health-treatment-at-scale) — Source: LifeStance Health
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)